Angiogenesis in JAK2 V617F positive myeloproliferative neoplasms and ruxolitinib decrease VEGF, HIF-1 enesis in JAK2 V617F positive cells

References

• Medinger M, Passweg J. Role of tumour angiogenesis in haematological malignancies. Swiss Med Wkly. 2014;144:w14050.
   PubMed Web of Science ®Google Scholar
• Li WW, Hutnik M, Gehr G. Antiangiogenesis in haematological malignancies. Br J Haematol. 2008;143:622–631.
   PubMed Web of Science ®Google Scholar
• Sanaat Z, Khalili R, Almasi S, et al. Does chemotherapy change expression of VEGF A&C and MVD in acute myeloid leukemia? Int J Hematol Oncol Stem Cell Res. 2014;8:24–29.
   PubMedGoogle Scholar
• Ribatti D, Vacca A. Role of endothelial cells and fibroblasts in multiple myeloma angiogenic switch. Cancer Treat Res. 2016;169:51–61.
   PubMedGoogle Scholar
• Subotički T, Mitrović Ajtić O, Beleslin-Čokić BB, et al. Angiogenic factors are increased in circulating granulocytes and CD34+ cells of myeloproliferative neoplasms. Mol Carcinog. 2017;56:567–579.
   PubMed Web of Science ®Google Scholar
• Chand R, Chandra H, Chandra S, et al. Role of microvessel density and vascular endothelial growth factor in angiogenesis of hematological malignancies. Bone Marrow Res. 2016;2016:5043483.
   PubMed Web of Science ®Google Scholar
• Masoud GN, Li W. HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B. 2015;5:378–389.
   PubMed Web of Science ®Google Scholar
• Treliński J, Wierzbowska A, Krawczyńska A, et al. Plasma levels of angiogenic factors and circulating endothelial cells in essential thrombocythemia: correlation with cytoreductive therapy and JAK2-V617F mutational status. Leuk Lymphoma. 2010;51:1727–1733.
   PubMed Web of Science ®Google Scholar
• Ramakrishnan S, Anand V, Roy S. Vascular endothelial growth factor signaling in hypoxia and inflammation. J Neuroimmune Pharmacol. 2014;9:142–160.
   PubMed Web of Science ®Google Scholar
• Unwith S, Zhao H, Hennah L, et al. The potential role of HIF on tumour progression and dissemination. Int J Cancer. 2015;136:2491–2503.
   PubMed Web of Science ®Google Scholar
• Medinger M, Passweg J. Angiogenesis in myeloproliferative neoplasms, new markers and future directions. Memo. 2014;7:206–210.
   PubMedGoogle Scholar
• Boveri E, Passamonti F, Rumi E, et al. Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations. Br J Haematol. 2008;140:162–168.
   PubMed Web of Science ®Google Scholar
• Tefferi A. Myeloproliferative neoplasms: a decade of discoveries and treatment advances. Am J Hematol. 2016;91:50–58.
   PubMed Web of Science ®Google Scholar
• Yacoub A, Odenike O, Verstovsek S. Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms. Curr Hematol Malig Rep. 2014;9:350–359.
   PubMed Web of Science ®Google Scholar
• Todorovic M, Radisavljevic Z, Balint B, et al. Increased angiogenesis-associated poor outcome in acute lymphoblastic leukemia. A single center study. Appl Immunohistochem Mol Morphol. 2012;20:488–493.
   Web of Science ®Google Scholar
• Wellmann S, Guschmann M, Griethe W, et al. Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF. Leukemia. 2004;18:926–933.
   PubMed Web of Science ®Google Scholar
• De Luisi A, Binetti L, Ria R, et al. Erythropoietin is involved in the angiogenic potential of bone marrow macrophages in multiple myeloma. Angiogenesis. 2013;16:963–973.
   PubMed Web of Science ®Google Scholar
• Lundberg LG, Lerner R, Sundelin P, et al. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am J Pathol. 2000;157:15–19.
   PubMed Web of Science ®Google Scholar
• Mizukami Y, Kohgo Y, Chung DC. Hypoxia inducible factor-1 independent pathways in tumor angiogenesis. Clin Cancer Res. 2007;13:5670–5674.
   PubMed Web of Science ®Google Scholar
• Medinger M, Skoda R, Gratwohl A, et al. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status. Br J Haematol. 2009;146:150–157.
   PubMed Web of Science ®Google Scholar
• Hatfield KJ, Bedringsaas SL, Ryningen A, et al. Hypoxia increases HIF-1α expression and constitutive cytokine release by primary human acute myeloid leukaemia cells. Eur Cytokine Netw. 2010;21:154–164.
   PubMed Web of Science ®Google Scholar
• Zeng D, Wang J, Kong P, et al. Ginsenoside Rg3 inhibits HIF-1α and VEGF expression in patient with acute leukemia via inhibiting the activation of PI3K/Akt and ERK1/2 pathways. Int J Clin Exp Pathol. 2014;7:2172–2178.
   PubMed Web of Science ®Google Scholar
• Dragoni S, Reforgiato M, Zuccolo E, et al. Dysregulation of VEGF-induced proangiogenic Ca2+ oscillations in primary myelofibrosis-derived endothelial colony-forming cells. Exp Hematol. 2015;43:1019–1030.
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Winton EF, Talpaz M, et al. Ruxolitinib for the treatment of patients with polycythemia vera. Expert Rev Hematol. 2015;8:391–401.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Komrokji RS, Verstovsek S. Ruxolitinib dose management as a key to long-term treatment success. Int J Hematol. 2016;104:420–429.
   PubMed Web of Science ®Google Scholar
• Kvasnicka HM, Thiele J. Bone marrow angiogenesis: methods of quantification and changes evolving in chronic myeloproliferative disorders. Histol Histopathol. 2004;19:1245–1260.
   PubMed Web of Science ®Google Scholar
• Legros L, Guilhot J, Huault S, et al. Interferon decreases VEGF levels in patients with chronic myeloid leukemia treated with imatinib. Leuk Res. 2014:38;662–665.
   PubMed Web of Science ®Google Scholar
• Gover-Proaktor A, Granot G, Shapira S, et al. Ponatinib reduces viability, migration, and functionality of human endothelial cells. Leuk Lymphoma. 2017;58:1455–1467.
   PubMed Web of Science ®Google Scholar